Literature DB >> 18305047

Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.

Patricia M Day1, Ratish Gambhira, Richard B S Roden, Douglas R Lowy, John T Schiller.   

Abstract

Pseudovirions of human papillomavirus type 16 (HPV16), the principal etiologic agent in 50% of cervical cancers, were used as a model system to investigate the cell surface interactions involved in the exposure of the broadly cross-neutralizing papillomavirus L2 epitopes. These neutralizing epitopes were exposed only after cell surface binding and a subsequent change in capsid conformation that permitted cleavage by the cellular protease furin at a specific highly conserved site in L2 that is immediately upstream of the cross-neutralizing epitopes. Unexpectedly, binding of L2 antibodies led to the release of the capsid/antibody complexes from the cell surface and their accumulation on the extracellular matrix. Study of the dynamics of exposure of the L2 epitopes further revealed that representatives of the apparently dominant class of L1-specific neutralizing antibodies induced by virus-like particle vaccination prevent infection, not by preventing cell surface binding but rather by preventing the conformation change involved in exposure of the L2 neutralizing epitope. These findings suggest a dynamic model of virion-cell surface interactions that has implications for both evolution of viral serotypes and the efficacy of current and future HPV vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305047      PMCID: PMC2293042          DOI: 10.1128/JVI.00143-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Clostridium septicum alpha-toxin is proteolytically activated by furin.

Authors:  V M Gordon; R Benz; K Fujii; S H Leppla; R K Tweten
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 3.  The influence of virus structure on antibody responses and virus serotype formation.

Authors:  M F Bachmann; R M Zinkernagel
Journal:  Immunol Today       Date:  1996-12

4.  A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera.

Authors:  Z Wang; N Christensen; J T Schiller; J Dillner
Journal:  J Gen Virol       Date:  1997-09       Impact factor: 3.891

5.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection.

Authors:  Ioannis Bossis; Richard B S Roden; Ratish Gambhira; Rongcun Yang; Mitsuo Tagaya; Peter M Howley; Patricio I Meneses
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.

Authors:  N D Christensen; J Dillner; C Eklund; J J Carter; G C Wipf; C A Reed; N M Cladel; D A Galloway
Journal:  Virology       Date:  1996-09-01       Impact factor: 3.616

8.  The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes.

Authors:  J G Joyce; J S Tung; C T Przysiecki; J C Cook; E D Lehman; J A Sands; K U Jansen; P M Keller
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

9.  Interaction of papillomaviruses with the cell surface.

Authors:  R B Roden; R Kirnbauer; A B Jenson; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.

Authors:  K R Klimpel; S S Molloy; G Thomas; S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more
  99 in total

1.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Authors:  Subhashini Jagu; Kihyuck Kwak; Robert L Garcea; Richard B S Roden
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

2.  Subunit interactions in bovine papillomavirus.

Authors:  Matthias Wolf; Robert L Garcea; Nikolaus Grigorieff; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

3.  Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses.

Authors:  Manuela Donalisio; Marco Rusnati; Andrea Civra; Antonella Bugatti; Donatella Allemand; Giovanna Pirri; Andrea Giuliani; Santo Landolfo; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

Review 4.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

5.  A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Authors:  Patricia M Day; Yuk-Ying S Pang; Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

6.  Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.

Authors:  Somayeh Pouyanfard; Gloria Spagnoli; Lorenzo Bulli; Kathrin Balz; Fan Yang; Caroline Odenwald; Hanna Seitz; Filipe C Mariz; Angelo Bolchi; Simone Ottonello; Martin Müller
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

7.  A transmembrane domain and GxxxG motifs within L2 are essential for papillomavirus infection.

Authors:  Matthew P Bronnimann; Janice A Chapman; Chad K Park; Samuel K Campos
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.

Authors:  Zurab Surviladze; Rosa T Sterk; Sergio A DeHaro; Michelle A Ozbun
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 9.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection.

Authors:  Zurab Surviladze; Rosa T Sterkand; Michelle A Ozbun
Journal:  J Gen Virol       Date:  2015-08       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.